US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SDEV $7.48 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

84.95 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crinetics Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Assessing Crinetics Pharmaceuticals: Insights From 4 Financial Analysts ↗
Throughout the last three months, 4 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ: CRNX), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments,... 
Via Benzinga
News headline image
Crinetics Pharma Surges After FDA OKs Its Treatment For A Form Of Gigantism ↗
The company's drug, Palsonify, treats acromegaly, a condition in which the pituitary gland makes too much growth hormone. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million. 
Via Benzinga
Retail Chatter Surges As Crinetics Wins FDA Nod For First Oral Acromegaly Drug — Traders Expect Big Price Move ↗
Via Stocktwits
News headline image
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Tuesday's pre-market session: top gainers and losers ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics (CRNX) Q2 Revenue Jumps 150% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly ↗
Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients over 84–96 weeks. 
Via Benzinga
News headline image
Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds ↗
The company presented new data at ENDO 2025 showing that patients who switched from monthly injections to the daily pill maintained hormone control and saw fewer symptom flare-ups over nearly two... 
Via Stocktwits
Topics Government
News headline image
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
JP Morgan Survey: 90% Of Endocrinologists Are Aware Of Crinetics' Atumelnant Data ↗
JP Morgan's survey of endocrinologists finds strong awareness of Crinetics' atumelnant, with positive efficacy impressions. Analysts see long-term potential. 
Via Benzinga
News headline image
Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology ↗
Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >